ERBB2 and breast carcinoma: More recent data have been consistent with earlier reports on the association of trastuzumab as adjuvant therapy for early-stage and locally advanced HER2-positive breast cancer with pauci-symptomatic decline in the left ventricular (LV) ejection fraction (EF), a measure of LV chamber systolic function, and with overt heart failure [46].